Provided herein are methods of treating basal cell carcinoma or glioblastoma by administering coal tar or a coal tar product to a patient with basal cell carcinoma or glioblastoma. The coal tar or coal tar product may be administered as a standalone therapy or in combination with other treatments for basal cell carcinoma or glioblastoma.

The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.

A compound of Structure (I): ##STR00001##
or a pharmaceutically acceptable salt thereof, alone or in combination with a second therapeutic agent, as well as methods of treating a PKM2-mediated disease or disorder using the same are provided herein.

A compound of Structure (I): ##STR00001##
or a pharmaceutically acceptable salt thereof, alone or in combination with a second therapeutic agent, as well as methods of treating a PKM2-mediated disease or disorder using the same are provided herein.

The invention relates to a composition for treatment and management of Dementia. The composition is a combination of herbs and bhasmas. It includes herbs such as Bacopa monnieri, Convolvulus pluricaulis, Mucuna pruriens, Nardostachys jatamansi, Rauwolfia serpentina, Withania somnifera, Acorus calamus, Sida cordifolia and Emblica officinalis. It further includes Shilajit, Rasa sindura and bhasmas. The composition is useful in treating Cognitive dysfunction, Dementia and other cognitive impairments associated with neuro-degenerative disorders. Further, the composition is also useful in restoring and improving cognitive function.

The invention relates to a composition for treatment and management of Dementia. The composition is a combination of herbs and bhasmas. It includes herbs such as Bacopa monnieri, Convolvulus pluricaulis, Mucuna pruriens, Nardostachys jatamansi, Rauwolfia serpentina, Withania somnifera, Acorus calamus, Sida cordifolia and Emblica officinalis. It further includes Shilajit, Rasa sindura and bhasmas. The composition is useful in treating Cognitive dysfunction, Dementia and other cognitive impairments associated with neuro-degenerative disorders. Further, the composition is also useful in restoring and improving cognitive function.

The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis. Epidermal barrier function can be significantly improved and the extraction of epidermal lipids can be reduced by using formulations containing high Krafft temperature surfactants, preferably, anionic surfactants.

The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis. Epidermal barrier function can be significantly improved and the extraction of epidermal lipids can be reduced by using formulations containing high Krafft temperature surfactants, preferably, anionic surfactants.

The disclosure relates to compositions and methods of treating cancer in a subject. The method comprises administering to a patient in need of treatment an effective amount of supercritical CO.sub.2 neem extract. The disclosure also relates to a process for preparing a CO.sub.2 extract of Azadirachta indica and herbal compositions thereof for the treatment of oral and colon cancers. The methods comprise a process for preparing a standardized SCO.sub.2 extract of Azadirachta indica leaves and herbal compositions of the same for oral use.

The invention provides a method and/or composition for the treatment of bone cancer including primary bone cancer and secondary bone cancer, breast cancer, skin cancer, nasopharyngeal carcinoma, oral cancer, vulva cancer, prostate cancer, cervical cancer, melanoma including melanocarcinoma by percutaneous and/or transmucosal administration of the interferon. Further, the invention provides a method and/or composition for the treatment of skin, subcutaneous, mucosal and/or submucosal primary cancer and cancer metastatic lesions by percutaneous and/or transmucosal administration of the interferon, especially a method and/or composition for the treatment of bone cancer pain including pain resulted by secondary bone cancer.